Last reviewed · How we verify
NCT04655469: TRAIN
Personal Health Train for Radiation Oncology in India and The Netherlands
trial in Head and Neck Carcinoma in 2,000 participants. Participants enrolled and being followed up; not accepting new ones.
15 May 2024
Quick facts
| Lead sponsor | Maastricht Radiation Oncology |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 10 April 2020 |
| Primary completion | 15 May 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 3 locations across Netherlands, India |
Conditions studied
- Head and Neck Carcinoma — all drugs for Head and Neck Carcinoma →
Sponsor
Maastricht Radiation Oncology — full company profile →
Who can join
18 and older, any sex, with Head and Neck Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary and general objective of this protocol as the current standard of care is to improve the quality of radiotherapy for HNC patients. This will ultimately be achieved by optimizing locoregional tumour control and overall survival and by reducing radiation-induced side effects. It will also allow the assessment of the effects of newly introduced radiation technology (e.g. proton therapy) for this particular group of patients. The clinical introduction of this standard follow-up program (SFP) will allow for a systematic and broad scale quality improvement cycle for HNC patients treated with radiotherapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Federated Prediction Models and External Validation for Radiotherapy Outcomes in Oropharyngeal Cancer using F.A.I.R. Clinical and Radiomics Data
Gouthamchand V, Gottardelli B, Kulkarni G, Sherkhane UB, et al · · 2025 · DOI 10.1101/2025.01.29.25321214 -
FAIR-ification of structured Head and Neck Cancer clinical data for multi-institutional collaboration and federated learning
Gouthamchand V, Choudhury A, Hoebers F, Wesseling F, et al · · 2023 · DOI 10.21203/rs.3.rs-2705743/v1
Verify or expand the search:
- PubMed search for NCT04655469
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Head and Neck Carcinoma
Currently open trials in the same condition.
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07227792 — Tongue-out Radiation Therapy (TORT) for the Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck · NA · recruiting
- NCT06896695 — A Financial Intervention (Financial Compass) to Identify and Address Financial Hardship Among Head and Neck Cancer Patie · NA · recruiting
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
- NCT06985784 — Virtual Reality Interventions for the Improvement of Depression, Anxiety and Pain in Patients With Head and Neck Cancer · NA · recruiting
Other Maastricht Radiation Oncology trials
Trials by the same sponsor.
- NCT07501845 — Registry Maastro Applicator · recruiting
- NCT07004582 — Lab Research Using Mini-tumors to Study Prostate Cancer Treatments · not yet recruiting
- NCT06024941 — Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer · Phase 2 · withdrawn
- NCT05182437 — Precision Radiation Treatment for Epilepsy (PRECISION) · NA · active not recruiting
- NCT02432417 — The Addition of Chloroquine to Chemoradiation for Glioblastoma, · Phase 2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04655469 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maastricht Radiation Oncology
- Last refreshed: 22 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04655469.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing